Loading...
Loading...
India's metoprolol imports from SWEDEN total $4565.7B across 52 shipments from 6 foreign suppliers. M/S. ASTRAZENECA AB leads with $4550.7B in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include ASTRAZENECA PHARMA INDIA LIMITED. This corridor reflects India's pharmaceutical import demand for metoprolol โ a diversified sourcing base with multiple active suppliers from SWEDEN.

M/S. ASTRAZENECA AB is the leading Metoprolol supplier from SWEDEN to India, with import value of $4550.7B across 33 shipments. The top 5 suppliers โ M/S. ASTRAZENECA AB, M S ASTRAZENECA AB, MS ASTRAZENECA AB, ASTRAZENECA AB, ACCORD FARMACEUTCA LTDA โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | M/S. ASTRAZENECA AB | $4550.7B | 33 | 99.7% |
| 2 | M S ASTRAZENECA AB | $15.0B | 7 | 0.3% |
| 3 | MS ASTRAZENECA AB | $391.0K | 4 | 0.0% |
| 4 | ASTRAZENECA AB | $216.9K | 3 | 0.0% |
| 5 | ACCORD FARMACEUTCA LTDA | $3.3K | 3 | 0.0% |
| 6 | SPRING BIO SOLUTION | $1.1K | 2 | 0.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ASTRAZENECA PHARMA INDIA LIMITED | $4565.7B | 47 | 100.0% |
| 2 | INTAS PHARMACEUTICALS LTD. | $3.3K | 3 | 0.0% |
| 3 | MICRO LABS LIMITED |
SWEDEN โ India trade corridor intelligence
The Sweden to India trade corridor for pharmaceutical imports is currently stable. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion reported. Freight rates have remained consistent over the past year, and the exchange rate between the Indian Rupee (INR) and the Swedish Krona (SEK) has shown moderate fluctuations, not significantly impacting trade volumes. Logistics providers continue to offer reliable services, ensuring timely deliveries of Metoprolol formulations.
The Indian government's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce import dependency. While this initiative encourages local production, it may impact the volume of finished pharmaceutical formulation imports, including Metoprolol. However, the PLI scheme also recognizes the need for high-quality imported medicines, and imports from countries like Sweden are likely to continue, especially for specialized formulations not produced domestically.
| $1.1K |
| 2 |
| 0.0% |
India and Sweden share a strong trade relationship, with ongoing discussions to enhance pharmaceutical trade. Negotiations for a Free Trade Agreement (FTA) are underway, aiming to reduce trade barriers and facilitate smoother exchanges. Mutual recognition of Good Manufacturing Practices (GMP) standards is being explored to streamline regulatory approvals. These efforts are expected to further strengthen the pharmaceutical trade corridor between the two nations.
The landed cost of importing Metoprolol formulations from Sweden to India includes several components:
Per-unit estimates can be calculated by dividing the total landed cost by the number of units imported. It's advisable to consult with a customs broker or logistics provider to obtain precise calculations based on current rates and specific shipment details.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Metoprolol into India, foreign manufacturers must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The registration process involves submitting Form 40 or 41, along with necessary documentation such as a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and compliance with regulatory requirements. For formulations under HS Code 30049074, specific requirements include detailed product information, manufacturing site details, and evidence of compliance with international quality standards. It's essential to ensure that all documents are current and accurately reflect the product's specifications to facilitate a smooth approval process.
Imported Metoprolol formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with the Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported goods. These inspections may include sampling and testing to ensure that the formulations meet the required standards for safety, efficacy, and quality.
Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Additionally, bilateral agreements between India and Sweden have streamlined the approval process for Swedish pharmaceutical products, facilitating smoother trade relations. These policy changes aim to balance the promotion of domestic industry with the need for high-quality imported medicines.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Metoprolol formulations to meet the demand for specific dosage forms and branded products not available domestically. The domestic capacity for manufacturing Metoprolol formulations is limited, leading to a reliance on imports to fulfill market needs. The market size for Metoprolol formulations in India is substantial, with a growing patient population requiring hypertension management. Imports from Sweden, particularly from manufacturers like AstraZeneca AB, provide high-quality formulations that cater to this demand.
The import of Metoprolol formulations under HS Code 30049074 into India is subject to a Basic Customs Duty of 10%, an Integrated Goods and Services Tax (IGST) of 12%, and a Social Welfare Surcharge (SWS) of 10%. These duties are calculated on the assessable value, which includes the Cost, Insurance, and Freight (CIF) value plus a 1% landing charge. Anti-dumping duties may apply if the Directorate General of Trade Remedies (DGTR) determines that imports are causing injury to the domestic industry. Exemption notifications may apply under specific conditions, such as for products imported under Free Trade Agreements (FTAs). The total landed duty percentage can vary based on the product's CIF value and applicable exemptions.
India sources Metoprolol formulations from Sweden due to the competitive advantages offered by Swedish manufacturers. Companies like AstraZeneca AB provide patented formulations and specialized dosage forms that are not readily available from other suppliers. Sweden's adherence to high-quality manufacturing standards and compliance with international regulatory requirements further enhance its position as a preferred source. While other countries like China, Germany, and the United States also supply Metoprolol formulations, Sweden's unique combination of quality, innovation, and reliability makes it a valuable partner for Indian importers.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Metoprolol formulations from Sweden due to the availability of patented formulations and specialized dosage forms that are not produced domestically. Swedish manufacturers, such as AstraZeneca AB, offer high-quality products that meet international standards, ensuring efficacy and safety. The advanced technology and research capabilities of Swedish pharmaceutical companies contribute to the development of innovative formulations, making them a preferred choice for Indian importers seeking to provide diverse treatment options to patients.
When compared to other origins like China, Germany, and the United States, Sweden offers distinct advantages in the supply of Metoprolol formulations. Swedish products are known for their high quality, adherence to international regulatory standards, and innovative formulations. While other countries may offer competitive pricing, Sweden's commitment to quality and reliability makes it a preferred source for Indian importers seeking consistent and effective pharmaceutical products.
Indian importers face several supply chain risks when sourcing Metoprolol formulations from Sweden. These include potential disruptions due to regulatory changes, currency fluctuations between the INR and SEK, and logistical challenges such as shipping delays or port congestion. To mitigate these risks, importers should establish strong relationships with Swedish suppliers, monitor regulatory developments, and maintain flexible logistics strategies. Diversifying the supplier base and maintaining adequate inventory levels can also help in managing potential supply chain disruptions.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Metoprolol suppliers from SWEDEN to India include M/S. ASTRAZENECA AB, M S ASTRAZENECA AB, MS ASTRAZENECA AB. The leading supplier is M/S. ASTRAZENECA AB with import value of $4550.7B USD across 33 shipments. India imported Metoprolol worth $4565.7B USD from SWEDEN in total across 52 shipments.
India imported Metoprolol worth $4565.7B USD from SWEDEN across 52 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Metoprolol sourced from SWEDEN include ASTRAZENECA PHARMA INDIA LIMITED, INTAS PHARMACEUTICALS LTD., MICRO LABS LIMITED. The largest buyer is ASTRAZENECA PHARMA INDIA LIMITED with $4565.7B in imports across 47 shipments.
The total value of Metoprolol imports from SWEDEN to India is $4565.7B USD, across 52 shipments and 6 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
52 Verified Shipments
6 suppliers, 3 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists